Investing.com - (NYSE:Allergan) first quarter earnings beat estimates.
The pharmaceutical reported diluted Q1 EPS of $3.35 v.s estimate of $3.29 and $2.99 a year earlier.
Revenues of the maker of Botox rose 5% from a year earlier to $3.6 bn vs. estimate of $3.53 bn.
Its guidance for full-year 2017 is diluted EPS within a range of $15.85-$16.35